Floatz logo

Vatreptacog Alfa

Haemophilia A

Novo Nordisk A/SPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

67 Active assets in the Haemophilia A cohort.

Asset / SponsorPhaseRating
Turoctocog Alfa
Novo Nordisk A/S
Phase 4A
Eptacog Alfa
AryoGen Pharmed Co.
Phase 4A
Rurioctocog Alfa Pegol
Takeda
Phase 4BBB
Turoctocog Alfa Pegol
Novo Nordisk A/S
Phase 3BBB
Immunoglobulin G4 [230-proline,de-449-lysine], anti-(human blood-coagulation factor IX)(human clone 0365-0001-9985 ?4-chain), disulfide with human clone 0365-0001-9985 ?-chain, (228?226?),(231?229?)-bis(disulfide) with anti-(human blood-coagulation factor X) immunoglobulin G4 [228-proline,405-leucine,409-lysine,de-447-lysine] (human clone 0365-0001-8174 ?4-chain) disulfide with human clone 0365-0001-8174 ?-chain
Novo Nordisk A/S
Phase 3BBB

View all 50 →

Same molecule, other indications

Vatreptacog Alfa is also rated in:

inherited blood coagulation disorderDormant
BB
Indicative ·
69 / 100
View asset →
hemophilia BDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →